Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NEUROMETRIX, INC.

(NURO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

NeuroMetrix Shares Continue to Rise on Tuesday's Breakthrough Designation for Quell

07/21/2021 | 10:24am EDT

By Chris Wack

NeuroMetrix Inc. shares continued to move up, doubling to $22.05 after saying Tuesday that its Quell device received Breakthrough Designation from the U.S. Food and Drug Administration for treating fibromyalgia in adults.

Volume for the stock was 28 million shares at 10 a.m. EDT, compared to its 65-day average volume of 4.4 million shares. The stock closed Tuesday's session up 208%.

The company said Quell is an advanced, non-invasive, nerve stimulation device that is covered by 18 U.S. utility patents, using position and motion sensing to automatically adjust stimulation for an optimal patient experience both day and night.

The FDA Breakthrough Device Program is intended to help patients receive more timely access to breakthrough technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions.

Under the program, the FDA will provide NeuroMetrix with priority review and interactive communication regarding device development, through to commercialization. In addition, there are government policies and programs under consideration that, if eventually adopted, may facilitate Medicare reimbursement for FDA Breakthrough Devices following marketing authorization.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

07-21-21 1023ET

All news about NEUROMETRIX, INC.
07/26NEUROMETRIX : Announces Peer-Reviewed Publication of a Randomized Controlled Tri..
AQ
07/22NEUROMETRIX : Q2 Loss Narrows as Revenue Climbs
MT
07/22NEUROMETRIX : Management's Discussion and Analysis of Financial Condition and Re..
AQ
07/22Wall Street Wavers Pre-Bell as Jobless Claims Rise
MT
07/22Top Pre-Market Gainers
MT
07/22NEUROMETRIX : Reports Q2 2021 Financial Results (Form 8-K)
PU
07/22NEUROMETRIX, INC. : Results of Operations and Financial Condition, Financial Sta..
AQ
07/22NEUROMETRIX : Earnings Flash (NURO) NEUROMETRIX Reports Q2 Revenue $2.2M
MT
07/22NEUROMETRIX : Reports Q2 2021 Financial Results
AQ
07/22NeuroMetrix, Inc. Announces Unaudited Consolidated Earnings Results for the S..
CI
More news
Financials (USD)
Sales 2020 7,38 M - -
Net income 2020 -2,09 M - -
Net cash 2020 4,17 M - -
P/E ratio 2020 -4,55x
Yield 2020 -
Capitalization 83,9 M 83,9 M -
EV / Sales 2019 0,28x
EV / Sales 2020 1,06x
Nbr of Employees 20
Free-Float 99,4%
Chart NEUROMETRIX, INC.
Duration : Period :
NeuroMetrix, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEUROMETRIX, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Managers and Directors
Shai N. Gozani Chairman, President & Chief Executive Officer
Thomas T. Higgins Chief Financial Officer, Treasurer & Senior VP
David E. Goodman Independent Director
Nancy E. Katz Independent Director
David van Avermaete Independent Director
Sector and Competitors
1st jan.Capi. (M$)
NEUROMETRIX, INC.371.52%84
ABBOTT LABORATORIES10.49%214 960
MEDTRONIC PLC12.10%176 468
BECTON, DICKINSON AND COMPANY2.21%74 377
ALIGN TECHNOLOGY, INC.30.21%55 063
SARTORIUS STEDIM BIOTECH65.28%52 629